Immunogenicity and Reactogenicity of a Reduced Schedule of a 4-component Capsular Group B Meningococcal Vaccine: A Randomized Controlled Trial in Infants

Clustered intergenic region sequences as predictors of factor H Binding Protein expression patterns and for assessing Neisseria meningitidis strain coverage by meningococcal vaccines

(2018) Caroline Cayrou et al.   PLoS One

Divergent Memory B Cell Responses in a Mixed Infant Pneumococcal Conjugate Vaccine Schedule

(2017) Johannes Trück et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Reduced schedules of 4CMenB vaccine in infants and catch-up series in children: Immunogenicity and safety results from a randomised open-label phase 3b trial

(2017) Federico Martinón-Torres et al.   VACCINE

Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24 months and immunogenicity of a fifth dose administered at 4 years of age-a phase 3 extension to a randomised controlled trial

(2017) Mildred A. Iro et al.   VACCINE

High-dimensional assessment of B-cell responses to quadrivalent meningococcal conjugate and plain polysaccharide vaccine

(2017) Daniel O’Connor et al.   Genome Medicine

Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study

(2016) Sydel R Parikh et al.   LANCET

Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months

(2015) Fiona McQuaid et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

The introduction of the meningococcal B (MenB) vaccine (Bexsero®) into the national infant immunisation programme – New challenges for public health

(2015) Shamez N. Ladhani et al.   JOURNAL OF INFECTION

Persistence of Bactericidal Antibodies to 5 Years of Age After Immunization With Serogroup B Meningococcal Vaccines at 6, 8, 12 and 40 Months of Age

(2014) Fiona McQuaid et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials

(2013) Timo Vesikari et al.   LANCET

Immunogenicity and Tolerability of Recombinant Serogroup B Meningococcal Vaccine Administered With or Without Routine Infant Vaccinations According to Different Immunization Schedules

(2012) Nicoletta Gossger et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

B Cell Memory to a Serogroup C Meningococcal Conjugate Vaccine in Childhood and Response to Booster: Little Association with Serum IgG Antibody

(2012) K. P. Perrett et al.   JOURNAL OF IMMUNOLOGY

Reference values for B cell subpopulations from infancy to adulthood

(2010) H. Morbach et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Plasma and memory B-cell kinetics in infants following a primary schedule of CRM197-conjugated serogroup C meningococcal polysaccharide vaccine

(2009) Dominic F. Kelly et al.   IMMUNOLOGY